Chemoprevention after polipectomy Giuseppe Aprile Gianpiero Fasola Dipartimento di Oncologia Azienda Ospedaliero-Universitaria di Udine Why is chemoprevention so complicated? Different studies with different endpoints, in different populations Drug companies contributed to the land of confusion Candidate Agents • • • • • • Aspirine Other NSAIDs and COX-2 inhibitors Difluoromethylornithine (DFMO) Diet and Nutraceuticals Antioxidants/Vitamins Statins Systematic review of the available evidence (19702005) on the effectiveness of aspirin for the chemoprevention of colic adenomas, CRC, and CRC mortality, as well as potential harms. 4 Bottom-line • Aspirina riduce il RR di adenoma colorettale in RCTs (RR 0.83, CI 0.7-0.95), studi caso-controllo (RR 0.75 CI 0.610.85), e in studi di coorte (RR 0.72, CI 0.61-0.85) • Se average-risk RR reduction nell’incidenza di adenoma 15-20%, possibliy higher se rischio maggiore • Contrastato il ruolo nella riduzione dell’incidenza di CRC (studi di coorte positivi, RCT negativi) • Dati insufficienti per mortalità • Benefici della chemioprevenzione più consistenti con uso di aspirina ad alte dosi per almeno 10 yrs • Possible harms (GI bleeding) require careful consideration Metanalisi di RCT sul ruolo dell’aspirina nella chemioprevenzione dell’adenoma colorettale Trial and ref. N Pop Treatment Prevention of any adenoma Prevention of advanced adenoma AFPPS Baron JA NEJM 2003 1120 Sporadic adenoma Placebo vs asp-81 vs asp-325 +/-FA + + CALGB 9270 Sandler R NEJM 2003 635 Previuos CRC Placebo vs asp-325 + - UK-CAP Logan R Gastroenterology 2008 940 Sporadic adenoma Placebo vs asp-300 + + APACC Benamouzig R, Gastroenterology 2003 270 Sporadic adenoma Placebo vs asp-160 vs asp-300 +/- +/- Cole BF, et al. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. JNCI 2009 Is Adenoma Recurrence a Useful Surrogate for CRC Risk? • Most small adenomatous polyps do not progress to malignancy Probability that a small adenoma contains high grade dysplasia/malignant changes is small (2%) • Average transition time from small adenoma to invasive cancer > 10 years National Polyp Study. N Engl J Med,1993 Number Needed to Treat (NNT) • Chemoprevention 10,000/15 = 700 treated for one cancer prevented 700 healthy people at risk for each person who benefits • Treatment of Disease (best case) 1 treated for one therapeutic effect 1 person at risk for each person who benefits Safety: Study Population • Geriatric patient (>70 yrs, >85 yrs if surgeon) susceptibilities – Severe drug toxicity – Drug-drug interactions • Potential for drug toxicity related to chronic administration • Reduction of adenoma growth but dysplasia and CRC changes may continue Selective COX-2 Inhibitors Celecoxib: 2001 FDA approved for adenomatous polyp prevention for individuals with FAP These data and retrospective data have led to extensive study of COX-2 inhibitors for sporadic adenomas as well Coxibs Cardiovascular Toxicity Celecoxib • APC Trial • N=2,035 subjects • Follow-up = 2.8-3.1 years • CV deaths (%) –Placebo (1%); RR=1.0 –200 mg BID (2.3%) RR=2.3 –400 mg BID (3.4%) RR=3.4 N Engl J Med. 2005;352:1071-80 Rofecoxib • APPROVe Trial • N=2,586 subjects • Follow-up = 3,327 pt-years • CV Adverse events (%) –Placebo (2%) RR=1.0 –25 mg QD (3.6%) RR=1.9 N Engl J Med. 2005;352:1092-102 Celecoxib, CRC prevention, safety issues Psaty and Potter, N Engl J Med 2006 Reviewed APC and PreSAP trials and concluded: – Celecoxib decreases adenoma formation – Celecoxib increases the risk of cardiovascular adverse events – The potential increase in CV event/mortality outweighs the projected decrease in colon cancer incidence Rofecoxib, CRC prevention, safety issues Kerr D et al. N Engl J Med 2007 Rofecoxib and cardiovascular adverse events in adjuvant treatment of CRC Reviewed VICTORe trial CV events, after a median treatment duration of 7.5 months: – Rofecoxib decreases adenoma formation – Rofecoxib significantly increases the risk of cardiovascular adverse events – RR for cardiovascular events 2.7 (CI 1.1-6.8) Do you see any improvement? 2000 2009